Hub & Spoken.

What's in this podcast?

In this podcast, Jason talks to Sam Herbert, Chief Operating Officer at Clinigen. Together, they discuss the pros and cons of expanding a data framework globally from an operations perspective.

Listen to this episode on Spotify, iTunes, and Stitcher. You can also catch up on the previous episodes of the Hub & Spoken podcast when you subscribe.

What are your thoughts on this topic? We’d love to hear from you; join the #HubandSpoken discussion and let us know on Twitter and LinkedIn.

For more on data, take a look at the webinars and events that we have lined up for you.

One Big Message

If there’s one thing that businesses of all sizes and industries can agree on, it’s the importance of data. Data is essential to understand customers, improve products, and make strategic decisions. However, to globally scale data infrastructure in the pharmaceutical industry, and also maintain privacy and efficiency, is a major task that requires a solid foundation to expand upon.

[00:30] Sam’s career and how Clinigen helps pharmaceutical companies adapt to different global markets

[05:40] How Clinigen utilises data in their organisation

[12:14] How top level management perceive data and its importance in the organisation

[17:50] Conveying the value of the data and foundational work to everyone

[23:00] Expanding on data foundations and growing data infrastructure

[31:07] Striking the balance between centralised and decentralised data

Setting up and maintaining ethical pipelines

One of the major issues in healthcare and pharmaceutical companies is ethical data management. Maintaining ethical pipelines is also a big feat, with the globalisation of companies requiring more and more data infrastructure to help with increasing demands.

From an operations perspective, there are many stakeholders who need to ensure that the data being collected, processed and used is both accurate and aligns with the company’s values. Pharmaceutical companies should work with their suppliers and customers to create an infrastructure that is transparent, responsible and meets all regulatory requirements.

Improve efficiency and accuracy in data

Big data is changing the pharmaceutical industry as we know it. With the ability to process and use large amounts of data, companies can develop and distribute new drugs and therapies at a much faster pace.

As a company grows, there’s increasing pressure to demonstrate the quality, reproducibility and integrity of data. Other factors come into play when a company goes into international markets. Data needs to be gathered and analysed for each region, as trends can vary significantly.

Data from the perspective of top-level management

Top-level management is equally invested in data – they just view it from a different perspective. While most people are interested in how data can help us improve our individual performance, top-level management is more interested in how data can be used to improve organisational performance.

In other words, they’re interested in what the numbers can tell them about their business.

Striking the balance between centralised and decentralised data

Using data at a global scale has its challenges. In order to ensure data accuracy and efficiency in a global company, various strategies must be used. One important factor is the use of technology to merge and cleanse data and choosing what needs to be centralised and decentralised. This can help streamline processes and only decentralise what is necessary, reducing the possibility of errors occuring.

To summarise

If there’s one thing that businesses of all sizes and industries can agree on, it’s the importance of data. Data is essential for understanding customers, improving products, and making strategic decisions especially at global scale.  By creating a solid data foundation, companies are able to expand their capabilities globally, and also maintain data accuracy and efficiency.